The effect of glucagon-like peptide1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: analysis of the LEADER and SUSTAIN 6 trials
Lower doses may be reasonable for some patients, but microdosing is still off-label, and the strongest evidence still comes from standard therapeutic dosing in populations with clinical obesity or metabolic disease, and many of the broader claims around low-dose use exceed what the evidence supports
Your dose may need to go up as your body adapts to treatment, but your price won't increasePlexusDx maintains flat monthly pricing across all dose levels
GLP-1 receptor agonists like semaglutide affect glucose metabolism, pancreatic function, and inflammation markerschanges that show up in your lab results
For queries, complaints, or support, please contact [email protected]